| Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. | |
| | |
MedLine Citation:
|
PMID: 19962416 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Despite clozapine's unique effectiveness in patients with schizophrenia, a number of adverse effects have been recognised including abnormalities in lipid and glucose metabolisms. A high clozapine level in red blood cells (RBCs) and disturbed anti-oxidant enzyme activities in blood from schizophrenic patients prompted us to investigate lipid status and anti-oxidant enzyme defence in the blood of chronic schizophrenic patients on long-term clozapine therapy. METHODS: Plasma lipids, RBC anti-oxidant enzyme activities and haemoglobin (Hb) content were measured using established procedures in a group of eighteen chronically-medicated (average 630 days of therapy) schizophrenic patients receiving clozapine (average dose of 295 mg/day) and data were compared with those from a group of eighteen well-matched normal controls. RESULTS: Significantly higher levels of plasma triglycerides (by 47%, p<0.01) and total cholesterol and phospholipids (by 8% and 11%, respectively p<0.05) in patients were found. CuZn-superoxide dismutase (SOD1) activity was markedly higher (by 35%, p<0.001) while selenium-dependent glutathione peroxidase (GSH-Px1) activity was markedly lower (by 41%, p<0.001) in patients. In addition, metHb and HbA1c levels in patients were significantly higher (by 58% and 25%, respectively p<0.001). SOD1 activity was negatively correlated (p<0.001) to GSH-Px1 activity in patients. CONCLUSIONS: The findings support the view that ongoing oxidative stress may be a mechanism by which clozapine induces some adverse effects that increase the risk of diabetes and metabolic syndrome. If valid, this would indicate that in parallel with long-term clozapine treatment, schizophrenic patients could be encouraged to make some lifestyle changes to limit the detrimental effects of the medication. |
| | |
Authors:
|
Cedo Miljevic; Milan Nikolic; Aleksandra Nikolic-Kokic; David R Jones; Vesna Niketic; Dusica Lecic-Tosevski; Mihajlo B Spasic |
Related Documents
:
|
22246146 - Ct colonography without cathartic preparation: positive predictive value and patient ex... 18261886 - Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by... 1798826 - Deficit syndrome in older schizophrenic patients. 9000316 - The stroop effect in schizophrenic patients. 7363686 - Atenolol in hypertension: a cardioselective drug. 7775506 - Acute pseudo-obstruction in critically ill patients with burns. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-12-03 |
Journal Detail:
|
Title: Progress in neuro-psychopharmacology & biological psychiatry Volume: 34 ISSN: 1878-4216 ISO Abbreviation: Prog. Neuropsychopharmacol. Biol. Psychiatry Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-22 Completed Date: 2010-05-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8211617 Medline TA: Prog Neuropsychopharmacol Biol Psychiatry Country: England |
Other Details:
|
Languages: eng Pagination: 303-7 Citation Subset: IM |
Copyright Information:
|
Copyright 2009 Elsevier Inc. All rights reserved. |
Affiliation:
|
Institute of Mental Health, Belgrade, Serbia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anthropometry / methods Antipsychotic Agents / pharmacology*, therapeutic use Body Composition / drug effects Body Mass Index Catalase / blood Clozapine / pharmacology*, therapeutic use Erythrocytes / drug effects*, enzymology Female Glutathione Peroxidase / blood Glutathione Reductase / blood Hemoglobins / metabolism* Humans Lipids / blood* Longitudinal Studies Male Schizophrenia / blood*, drug therapy Superoxide Dismutase / blood |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Hemoglobins; 0/Lipids; 5786-21-0/Clozapine; EC 1.11.1.6/Catalase; EC 1.11.1.9/Glutathione Peroxidase; EC 1.15.1.1/Superoxide Dismutase; EC 1.8.1.7/Glutathione Reductase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A review of the UK methodology used for monitoring cigarette smoke yields, aspects of analytical dat...
Next Document: KMUP-1 attenuates serum deprivation-induced neurotoxicity in SH-SY5Y cells: Roles of PKG, PI3K/Akt a...